Media coverage
6
Media coverage
Title Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib of APR-246 in ovarian cancer Degree of recognition International Media name/outlet Cyprus Mail Date 11/10/16 Persons Charlie Gourley Title Aprea Therapeutics announces efficacy and safety data in high-grade serous ovarian cancer patients treated with APR-246 in presentation at 2016 European Society for Medical Oncology (ESMO) annual meeting Degree of recognition International Media name/outlet PR Newswire Date 10/10/16 Persons Charlie Gourley Title Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib of APR-246 in ovarian cancer Degree of recognition International Media name/outlet Dow Jones Institutional News Date 10/10/16 Persons Charlie Gourley Title Aprea Therapeutics announces efficacy and safety data in high-grade serous ovarian cancer patients treated with APR-246 in presentation at 2016 European Society for Medical Oncology annual meeting Degree of recognition International Media name/outlet India Pharma News Date 10/10/16 Persons Charlie Gourley Title Aprea Therapeutics announces efficacy and safety data in high-grade serous ovarian cancer patients treated with APR-246 in presentation at 2016 European Society for Medical Oncology annual meeting Degree of recognition International Media name/outlet Pharmacy Choice Date 10/10/16 Persons Charlie Gourley Title Karolinska Development portfolio company Aprea Therapeutics updates clinical data from Phase Ib of APR-246 in ovarian cancer Degree of recognition International Media name/outlet NASDAQ OMX Nordic Exchanges Date 10/10/16 Persons Charlie Gourley